Edition:
India

Carl O'Donnell

Abbott says COVID-19 test demand to grow in 2021

21 Oct 2020

Abbott Laboratories said it expects demand for its COVID-19 tests to grow in 2021 even if a vaccine is developed and for the business to eventually stabilize into a lucrative new franchise.

UPDATE 3-Abbott says COVID-19 test demand to grow in 2021

21 Oct 2020

Oct 21 Abbott Laboratories said it expects demand for its COVID-19 tests to grow in 2021 even if a vaccine is developed and for the business to eventually stabilize into a lucrative new franchise.

Explainer: When will COVID-19 vaccines be generally available in the United States?

17 Oct 2020

U.S. President Donald Trump and the head of the Centers for Disease Control and Prevention (CDC) have disagreed about when a COVID-19 vaccine would become widely available. Trump has said enough vaccine would be available for every American by April, while the CDC director said vaccines were likely to reach the general public around mid-2021, an assessment more in line with most experts.

Q&A: Where are we in the COVID-19 vaccine race?

16 Oct 2020

NEW YORK Drugmakers and research centers around the world are working on COVID-19 vaccines, with large global trials of several of the candidates involving tens of thousands of participants well underway.

Top U.S. health official Fauci says Trump no longer coronavirus contagious: CBS interview

15 Oct 2020

U.S. President Donald Trump is no longer capable of spreading the novel coronavirus and can attend a town hall on Thursday without putting others at risk, top U.S. public health official Anthony Fauci said in an interview with CBS Evening News.

U.S. pauses Eli Lilly trial of antibody drug Trump touted as COVID-19 'cure' over safety concern

15 Oct 2020

(This Oct. 13 story corrects the headline and paragraphs 1 and 9 to show the federal government, not Eli Lilly, made the decision to pause a clinical trial of the company’s antibody drug) | Video

Eli Lilly says other COVID-19 antibody drug trials ongoing after study halted for safety concern

14 Oct 2020

Eli Lilly & Co on Wednesday said other trials of its experimental coronavirus antibody therapy remain on track after a government-run study testing the treatment in hospitalized COVID-19 patients was paused due to safety concerns. | Video

World News